Cannabis in Switzerland

Switzerland has taken a methodical approach to cannabis reform, combining a medical cannabis program with pilot programs testing regulated recreational sales in select cities. Medical cannabis was authorized in 2022 under simplified prescribing rules that allow physicians to prescribe cannabis without requiring special approval from the Federal Office of Public Health, significantly improving patient access.

Switzerland's most innovative contribution to cannabis policy is its pilot program framework. The Narcotics Act was amended in 2021 to allow municipalities to conduct scientific trials of regulated recreational cannabis sales. Basel, Zurich, Bern, and Lausanne are among the cities participating in these programs, which provide cannabis from regulated sources to registered adult participants while studying the public health and social effects of regulated access. These pilots are designed to generate evidence to inform future national policy decisions.

Switzerland has long been a center for cannabis-related commerce through its legal hemp market. Swiss law permits cannabis with less than 1% THC (compared to the 0.2-0.3% limit in most other countries), creating a robust market for low-THC cannabis products sold through tobacconists and specialty shops. This higher THC threshold has enabled the development of a unique Swiss cannabis products industry.

The Swiss approach is characteristically pragmatic, using evidence-based pilot programs rather than ideological policy positions. While not a member of the EU, Switzerland's policy decisions influence neighboring countries and contribute to the broader European conversation about cannabis regulation. The combination of medical access, recreational pilots, and a legal hemp market makes Switzerland one of the more dynamic cannabis policy environments in Europe.